EXINI and Active Biotech AB Present Impact of Tasquinimod on Bone Metastases as Measured by Bone Scan Index (BSI)

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EXINI Diagnostics AB (NASDAQ OMX First North: EXINI) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod combined with BSI - evaluation (Bone Scan Index) at the scientific conference “2013 ASCO (American Society of Clinical Oncology) Annual Meeting” held in Chicago (USA).

Help employers find you! Check out all the jobs and post your resume.